Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on equity-31.1%-5.9pp-25.2%+12.9pp-38.1%+11.7pp-49.8%+16.0pp-65.8%-6.5pp
Return on assets-26.9%-4.5pp-22.4%+9.8pp-32.2%+10.2pp-42.4%-2.9pp-39.5%+4.3pp
Liquidity
Current ratio-4.3×13.3×+2.3×10.9×+4.4×6.5×-1.6×8.1×-3.2×
Quick ratio-4.3×13.3×+2.3×10.9×+4.4×6.5×-1.6×8.1×-3.2×
Cash ratio1.1×-0.3×1.5×+0.1×1.4×+0.4×+0.3×0.7×-1.0×
Per Share
Book value per share$8.54-23.5%$11.17+48.2%$7.53-0.3%$7.55-5.7%$8.01-27.3%
Valuation
Market capitalization$3.96B+55.8%$2.54B+151%$1.01B+8.8%$930.05M-4.3%$972.25M-30.2%
Price / book5.9×+2.4×3.6×+1.3×2.2×+0.2×0.0×-0.7×
Earnings yield-4.5%+1.6pp-6.1%+8.6pp-14.7%+7.5pp-22.2%-0.7pp-21.5%-6.5pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Spyre Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Spyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.